Vaccination with DC/tumor fusion cells results in cellular and humoral anti-tumor immune responses in patients with multiple myeloma DC/myeloma fusion vaccine induces immune responses
Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Poorvi Somaiya(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Kenneth C. Anderson(Dana-Farber Cancer Institute), Lynne Uhl(Hadassah Medical Center), Nikhil C. Munshi(Dana-Farber Cancer Institute), Claire MacNamara, Simona Blotta(Harvard University), Karen Francoeur(Dana-Farber Cancer Institute), Donald Küfe(Dana-Farber Cancer Institute), Yan Emily Yuan(Beth Israel Deaconess Medical Center), Paul Richardson(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Baldev Vasir(Beth Israel Deaconess Medical Center), Dilani Dombagoda(Beth Israel Deaconess Medical Center), Zekui Wu(Dana-Farber Cancer Institute), Edie Weller(Boston Children's Hospital), James D. Levine(Beth Israel Deaconess Medical Center), Donna Fitzgerald(Beth Israel Deaconess Medical Center)
Unknown
January 1, 2017
Cited by 0
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k